Journals / Çocuk Enfeksiyon Dergisi / 2009 / Cilt: 3 - Sayı: 3

Aspergillus infections in children

Çocuklarda aspergillus enfeksiyonları

Pages
118–125
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

New drugs such as caspofungin and voriconazole are promising for the treatment of the pediatric patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aspergillus species are widespread in nature.
📊
Key Findings & Data:They cause three different diseases, including invasive disease, non-invasive disease and hypersensitivity syndromes.
💡
Conclusion & Impact:New drugs such as caspofungin and voriconazole are promising for the treatment of the pediatric patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aspergillus species are widespread in nature. They cause three different diseases, including invasive disease, non-invasive disease and hypersensitivity syndromes. Although they have many species, Aspergillus fumigatus and Aspergillus flavus are mainly responsible for human infections. Invasive infections in the immunocompromised patients cause particularly high mortality. Persistent fever not responding to antibiotics is usually the first clinical finding. The diagnosis can be established by the isolation of the fungus in culture, the demonstration of typical hyphea in the tissue samples, or serological tests. Amphotericin B, itraconazole, and flucytosine are the most commonly used drugs for the therapy. New drugs such as caspofungin and voriconazole are promising for the treatment of the pediatric patients.

Özet

Aspergillus türleri doğada yaygın olarak bulunurlar. İnsanlarda invaziv hastalık, invaziv olmayan hastalık ve aşırı duyarlılık sendromu olmak üzere üç farklı hastalık grubuna neden olurlar. Çok sayıda türü olmasına karşın insanlardaki enfeksiyonlardan başlıca Aspergillus fumigatus ve Aspergillus flavus sorumludur. Özellikle bağışıklık sisteminde sorun olan hastalarda ortaya çıkan invaziv enfeksiyonların mortalitesi yüksektir. Antibiyotiklere yanıt vermeyen ateş genellikle ilk klinik bulgudur. Tanı mantarın kültürde üretilmesi, dokuda tipik hif yapısının gösterilmesi veya serolojik testler ile konulabilir. Tedavide amfoterisin B, itrakonazol ve flusitozin en sık kullanılan ilaçlardır. Kaspofungin ve vorikonazol gibi yeni ilaçlar çocuk hastaların tedavisinde umut vericidir.

🔖

Cite This Article

AYBERKİN, E., ÇİFTÇİ, E. (2009). Aspergillus infections in children. Çocuk Enfeksiyon Dergisi, Cilt: 3 - Sayı: 3, 118–125. https://ajindex.com/articles/220212

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ayberkin E, Çiftçi E. Çocuklarda Aspergillus enfeksiyonları. Çocuk Enfeksiyon Hastalıkları Dergisi 2006; 1: 27-34
  2. Blum MD, Wiedermann BL. Aspergillus infections. In: Feigin RD, Cherry JD, Demmler GJ, Kaplan SL, eds. Textbook of Pediatric Infectious Diseases, 5th ed. Philadelphia, Saunders 2004: 2550-60
  3. Hajjeh RA, Warnock DW. Aspergillus species. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Diseases, 2nd ed. Philadelphia: Churchill Livingstone 2003: 1213-20
  4. Denning DW. Aspergillus species. In: Mandell GL, Bennet JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 5th ed. Philadelphia: Churchill Livingstone 2000: 2674-85
  5. Roilides E, Unlig K, Venzon D, et al. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993; 61: 4870-7
  6. Roilides E, Blake C, Holmes A, et al. Granulocyte-macrophage colony-stimulating factor and interferon-γ prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol 1996; 34: 63-9
  7. Allam MF, Del Castillo AS, Diaz-Molina C, Navajas RF. Invasive pulmonary aspergillosis: Identification of risk factors. Scand J Infect Dis 2002; 34: 819-22
  8. Muller FM, Trusen A, Weig M. Clinical manifestations and diagnosis of invasive aspergillosis in immunocompromised children. Eur J Pediatr 2002; 161: 563-74
  9. Segal BH, DeCarlo ES, Kwon-Chung KJ, Malech HL, Gallin JI, Holland SM. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 1998; 77: 345-54
  10. Choi SS, Milmoe GJ, Dinndorf PA, Quinones RR. Invasive Aspergillus sinusitis in pediatric bone marrow transplant patients: Evaluation and management. Arch Otolaryngol Head Neck Surg 1995; 121: 1188-92
  11. Kavanagh KT, Hughes WT, Parham DM, Chanin LR. Fungal sinusitis in immunocompromised children with neoplasms. Ann Otol Rhinol Laryngol 1991; 100: 331-6
  12. Panda NK, Balaji P, Chakrabarti A, Sharma SC, Reddy CEE. Paranasal sinus aspergillosis: Its categorization to develop a treatment protocol. Mycoses 2004; 47: 277-83
  13. Green M, Wald ER, Tzakis A, et al. Aspergillosis of the CNS in a pediatric liver transplant recipient: Case report and review. Rev Infect Dis 1991; 13: 653-7
  14. Robinson MR, Fine HF, Ross ML, Mont EK, Bryant-Greenwood PK, Hertle RW, Tis